DK1545560T3 - Sammensætninger til inhibering af proteinkinase C-alfa til behandling af diabetes mellitus - Google Patents

Sammensætninger til inhibering af proteinkinase C-alfa til behandling af diabetes mellitus

Info

Publication number: DK1545560T3
Authority: DK; Denmark
Prior art keywords: activity; treatment; protein kinase; diabetes mellitus; inhibition
Prior art date: 2002-09-24

Application number

DK03770876.5T

Other languages

English (en)

Inventor

Jan Menne

Hermann Haller

Original Assignee

Phenos Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-24

Filing date

2003-09-23

Publication date

2010-11-22

2003-09-23 Application filed by Phenos Gmbh filed Critical Phenos Gmbh

2010-11-22 Application granted granted Critical

2010-11-22 Publication of DK1545560T3 publication Critical patent/DK1545560T3/da

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 3
102000015537 Protein Kinase C-alpha Human genes 0.000 title 1
108010050276 Protein Kinase C-alpha Proteins 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1
230000000694 effects Effects 0.000 abstract 3
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000002402 anti-lipaemic effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
230000001966 cerebroprotective effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
210000003734 kidney Anatomy 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
230000007774 longterm Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
201000001474 proteinuria Diseases 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

DK03770876.5T 2002-09-24 2003-09-23 Sammensætninger til inhibering af proteinkinase C-alfa til behandling af diabetes mellitus DK1545560T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10244453A DE10244453A1 (de)	2002-09-24	2002-09-24	Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
PCT/DE2003/003165 WO2004028516A2 (de)	2002-09-24	2003-09-23	Zusammensetzungen zur hemmung der proteinkinase c alpha zur behandlung von diabetes mellitus und kardiovaskulärer erkrankungen

Publications (1)

Publication Number	Publication Date
DK1545560T3 true DK1545560T3 (da)	2010-11-22

Family

ID=31969524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03770876.5T DK1545560T3 (da)	2002-09-24	2003-09-23	Sammensætninger til inhibering af proteinkinase C-alfa til behandling af diabetes mellitus

Country Status (19)

Country	Link
US (2)	US20050250719A1 (da)
EP (2)	EP2338498A1 (da)
JP (1)	JP2006503841A (da)
KR (1)	KR20050059180A (da)
CN (1)	CN1684694A (da)
AT (1)	ATE475422T1 (da)
AU (1)	AU2003280288B2 (da)
CA (1)	CA2499818A1 (da)
DE (3)	DE10244453A1 (da)
DK (1)	DK1545560T3 (da)
EA (1)	EA007926B1 (da)
ES (1)	ES2356286T3 (da)
IS (1)	IS7777A (da)
MX (1)	MXPA05002930A (da)
NO (1)	NO20051242L (da)
NZ (1)	NZ538857A (da)
PL (1)	PL374829A1 (da)
UA (1)	UA88257C2 (da)
WO (1)	WO2004028516A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20031714A1 (it)	2003-09-05	2005-03-06	Gentium Spa	Formazioni ad azione antitumorale.
US20050066381A1 (en) *	2003-09-19	2005-03-24	Children's Hospital Medical Center	Regulation of cardiac contractility and heart failure propensity
WO2005038013A1 (en) *	2003-10-07	2005-04-28	Isis Pharmaceuticals, Inc.	Artisense oligonucleotides optimized for kidney targeting
US9144594B2 (en) *	2005-11-08	2015-09-29	University Of Miami	Cathepsin L mediated diseases and associated methods and products
JP2009518439A (ja) *	2005-12-09	2009-05-07	メタプロテオミクス，エルエルシー	ホップ及びアカシア産物によるプロテインキナーゼ調節
US20080181877A1 (en) *	2006-03-22	2008-07-31	Leangene Ab, C/O Cit Ekonomiservice Ab	Method For Monitoring the Effect of Compounds on Foxc2 Expression
US10369222B2 (en)	2012-01-18	2019-08-06	Biosuccess Biotech Co., Ltd.	Compositions and methods of use of phorbol esters for the treatment of stroke
US9974764B2 (en)	2007-01-31	2018-05-22	Biosuccess Biotech Co. Ltd.	Compositions and methods of use of phorbol esters in the treatment of neoplasms
US11564901B2 (en)	2007-01-31	2023-01-31	Biosuccess Biotech Co., Ltd.	Compositions and methods of use of phorbol esters
US9533938B2 (en)	2007-01-31	2017-01-03	Biosuccess Biotech Co., Ltd.	Compositions and methods of use of phorbol esters for the treatment of stroke
EP2170053A4 (en)	2007-01-31	2010-06-23	Biosuccess Biotech Company	Compositions and methods of use of phorbol esters
US11696908B2 (en)	2007-01-31	2023-07-11	Biosuccess Biotech Co. Ltd.	Compositions and methods of use of phorbol esters
US9636317B2 (en)	2007-01-31	2017-05-02	Biosuccess Biotech Co. Ltd.	Compositions and methods of use of phorbol esters
EP1982722A1 (en) *	2007-04-16	2008-10-22	Gentium S.p.A.	Use of oligotide for the treatment of renal diseases
US20120301463A1 (en)	2009-09-30	2012-11-29	President And Fellows Of Harvard College	Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
EP2637672B1 (en)	2010-11-12	2018-08-22	Gentium S.r.l.	Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
NZ727304A (en) *	2012-01-18	2018-08-31	Biosuccess Biotech Co Ltd	Compositions and methods of use of phorbol esters for the treatment of stroke
US10099996B2 (en)	2012-01-18	2018-10-16	Biosuccess Biotech Co. Ltd.	Compositions and methods of use of phorbol esters in the treatment of neoplasms
US9550722B2 (en)	2012-01-18	2017-01-24	Biosuccess Biotech Co. Ltd.	Compositions and methods of use of phorbal esters for the treatment of stroke
US20150079111A1 (en) *	2012-06-05	2015-03-19	Jonas Axelsson	Mechanism, diagnostic, and treatments for complications of renal failure
ES2660969T5 (es)	2012-06-22	2021-09-03	Gentium S R L	Método basado en euglobulina para determinar la actividad biológica de defibrotida
TWI630909B (zh) *	2013-01-18	2018-08-01	華鴻新藥股份有限公司	用於中風治療之巴豆酯組成物及使用方法
TWI687217B (zh) *	2014-01-10	2020-03-11	華鴻新藥股份有限公司	用於中風治療之巴豆酯組成物及使用方法
EP3501531A1 (en) *	2014-01-29	2019-06-26	Université de Strasbourg	New target for diabetes treatment and prevention
RU2738833C9 (ru) *	2014-04-14	2022-02-28	Арвинас, Оперэйшнз, Инк.	Имидные модуляторы протеолиза и способы их применения
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
EP3026122A1 (en)	2014-11-27	2016-06-01	Gentium S.p.A.	Cellular-based method for determining the potency of defibrotide
EP3313993A4 (en)	2015-06-29	2019-06-19	Regents of the University of Minnesota	ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE
EP3421485A1 (en)	2017-06-30	2019-01-02	Université de Strasbourg	Peptides for treatment and prevention of hyperglycaemia
US20190100929A1 (en) *	2017-09-29	2019-04-04	Safeworks, Llc	Hoist system with direct current power supply
RU2765117C2 (ru) *	2019-09-24	2022-01-25	Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина"	Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета
WO2022092884A1 (ko) *	2020-10-29	2022-05-05	가톨릭관동대학교산학협력단	13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3914764A1 (de) *	1989-05-05	1990-11-08	Goedecke Ag	Maleinimid-derivate und deren verwendung als arzneimittel
DE3924538A1 (de) *	1989-07-25	1991-01-31	Goedecke Ag	Indolocarbazol und dessen verwendung
JPH06501695A (ja) *	1990-10-01	1994-02-24	ブリガム・アンド・ウイメンズ・ホスピタル	主要血管事象を抑制するためのベータ−カロテン及びビタミンｅ療法
AU637014B2 (en) *	1990-11-02	1993-05-13	Sphinx Pharmaceuticals Corporation	Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase c
AU1783092A (en) *	1991-04-08	1992-11-02	United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The	Inhibitors of protein kinase c function
CA2179650C (en)	1993-12-23	2007-10-30	William Francis Heath, Jr.	Bisindolemaleimides and their use as protein kinase c inhibitors
US5481003A (en)	1994-06-22	1996-01-02	Eli Lilly And Company	Protein kinase C inhibitors
US5491242A (en)	1994-06-22	1996-02-13	Eli Lilly And Company	Protein kinase C inhibitors
SI0776895T1 (en) *	1995-11-20	1999-04-30	Eli Lilly And Company	Protein kinase C inhibitor
EA001450B1 (ru) *	1996-05-01	2001-04-23	Эли Лилли Энд Компани	Галогензамещенные ингибиторы протеинкиназы с
US6063814A (en) *	1997-04-14	2000-05-16	Chang; Richard L.	Phorbol esters as anti-neoplastic and white blood cell elevating agents
DE19740384A1 (de) *	1997-09-08	1999-03-11	Max Delbrueck Centrum	Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
US20050066381A1 (en) *	2003-09-19	2005-03-24	Children's Hospital Medical Center	Regulation of cardiac contractility and heart failure propensity

2002
- 2002-09-24 DE DE10244453A patent/DE10244453A1/de not_active Withdrawn
2003
- 2003-09-23 JP JP2004538744A patent/JP2006503841A/ja active Pending
- 2003-09-23 EA EA200500529A patent/EA007926B1/ru not_active IP Right Cessation
- 2003-09-23 DK DK03770876.5T patent/DK1545560T3/da active
- 2003-09-23 AT AT03770876T patent/ATE475422T1/de active
- 2003-09-23 AU AU2003280288A patent/AU2003280288B2/en not_active Ceased
- 2003-09-23 KR KR1020057004958A patent/KR20050059180A/ko not_active Ceased
- 2003-09-23 WO PCT/DE2003/003165 patent/WO2004028516A2/de not_active Ceased
- 2003-09-23 MX MXPA05002930A patent/MXPA05002930A/es active IP Right Grant
- 2003-09-23 DE DE50312935T patent/DE50312935D1/de not_active Expired - Lifetime
- 2003-09-23 PL PL03374829A patent/PL374829A1/xx unknown
- 2003-09-23 CN CNA038228017A patent/CN1684694A/zh active Pending
- 2003-09-23 US US10/528,806 patent/US20050250719A1/en not_active Abandoned
- 2003-09-23 NZ NZ538857A patent/NZ538857A/en unknown
- 2003-09-23 DE DE10393825T patent/DE10393825D2/de not_active Expired - Fee Related
- 2003-09-23 EP EP10170970A patent/EP2338498A1/de not_active Withdrawn
- 2003-09-23 EP EP03770876A patent/EP1545560B1/de not_active Expired - Lifetime
- 2003-09-23 UA UAA200503856A patent/UA88257C2/ru unknown
- 2003-09-23 CA CA002499818A patent/CA2499818A1/en not_active Abandoned
- 2003-09-23 ES ES03770876T patent/ES2356286T3/es not_active Expired - Lifetime
2005
- 2005-03-10 NO NO20051242A patent/NO20051242L/no not_active Application Discontinuation
- 2005-03-30 IS IS7777A patent/IS7777A/is unknown
2008
- 2008-12-01 US US12/325,930 patent/US20090191194A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IS7777A (is)	2005-03-30
EA007926B1 (ru)	2007-02-27
WO2004028516A2 (de)	2004-04-08
AU2003280288B2 (en)	2008-08-28
US20050250719A1 (en)	2005-11-10
CA2499818A1 (en)	2004-04-08
CN1684694A (zh)	2005-10-19
DE10244453A1 (de)	2004-04-01
NZ538857A (en)	2010-10-29
ATE475422T1 (de)	2010-08-15
MXPA05002930A (es)	2005-09-30
AU2003280288A1 (en)	2004-04-19
WO2004028516A3 (de)	2004-11-11
EP1545560A2 (de)	2005-06-29
EP1545560B1 (de)	2010-07-28
ES2356286T3 (es)	2011-04-06
NO20051242L (no)	2005-06-01
JP2006503841A (ja)	2006-02-02
UA88257C2 (ru)	2009-10-12
PL374829A1 (en)	2005-10-31
DE10393825D2 (de)	2005-08-11
US20090191194A1 (en)	2009-07-30
EA200500529A1 (ru)	2005-08-25
KR20050059180A (ko)	2005-06-17
DE50312935D1 (de)	2010-09-09
EP2338498A1 (de)	2011-06-29

Publication	Publication Date	Title
DK1545560T3 (da)	2010-11-22	Sammensætninger til inhibering af proteinkinase C-alfa til behandling af diabetes mellitus
ES2531660T3 (es)	2015-03-18	Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
NO20044534L (no)	2004-12-22	Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
NO20062292L (no)	2006-06-14	Fremgangsmate for behandling av transplantasjonsavstoting
ATE396190T1 (de)	2008-06-15	Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
DK1349843T3 (da)	2005-08-15	Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
WO2002066450A3 (en)	2002-12-05	Anthrone derivatives and their use as ink inhibitors
NO20015394L (no)	2002-05-07	Karboksylsyrederivater som hemmer bindingen av integriner til deres reseptorer
DK1076644T3 (da)	2004-08-30	N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser
BR0210167A (pt)	2004-04-06	Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
HK1054333A1 (zh)	2003-11-28	杂芳基脲神经肽yy5受体拮抗剂
DK1817065T3 (da)	2011-06-14	Viskoelastiske opløsninger indeholdende natriumhyaluronat og hydroxypropylmethylcellulose
WO2004024093A3 (en)	2004-07-29	Device and method for treating restenosis
PE20040291A1 (es)	2004-07-02	COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
MY147642A (en)	2012-12-31	Novel anthranilamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors
WO2005030187A3 (en)	2005-06-23	Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
BR0017157A (pt)	2002-11-26	Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
NO20083068L (no)	2008-07-08	Optisk aktive karbamater, fremgangsmate for deres fremstilling og anvendelse derav som farmasoytiske mellomprodukter
DK1336407T3 (da)	2006-09-04	Præparat indeholdende en angiotensin-II-receptorantagonist og et diuretikum og anvendelse deraf til behandling af hypertension
BRPI0406455A (pt)	2005-12-06	Combinação farmacêutica para profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais
ATE485049T1 (de)	2010-11-15	Physiologisch aktive zusammensetzung gegen diabetes
EP1602645A4 (en)	2008-12-03	NITROGENIC HETEROCYCLIC DERIVATIVE WITH 2,6-DISUBSTITUTED STYRYL REST
ATE401877T1 (de)	2008-08-15	Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen
DK1587584T3 (da)	2007-09-24	Farmaceutisk kombination til profylakse eller behandling af kardiovaskulære, kardiopulmonale, pulmonale eller renale sygdomme
DE602005008282D1 (de)	2008-08-28	Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1